Incretin Mimetics • Research Update

Mazdutide: New Dual-Acting Weight Loss Drug in Overview

While well-known weight loss injections like Wegovy (semaglutide) and Mounjaro (tirzepatide) dominate Western markets, a new generation of pharmaceuticals is emerging in Asia. With Mazdutide (also known by its laboratory designation IBI362), the biotechnology company Innovent Biologics has developed a compound based on a dual-activation mechanism that is already approved in China. Clinical trial results show strong weight reduction and favorable tolerability.

📋 Summary for the Quick Reader

Mechanism of Action: A dual-acting drug (GLP-1 and glucagon) that zips appetite ("eat less") while boosting the body's energy expenditure ("burn more").
Strong Efficacy: Clinical trials show an average body weight reduction of 14% in 48 weeks. This is comparable to Western market leaders but achieved faster.
Good Tolerability: Within the class of glucagon-containing agonists, Mazdutide exhibits the best safety profile, although typical gastrointestinal issues like nausea occur in the beginning.
Approval Status: Currently approved in China. Clinical trials are ongoing in the US and Europe, with approvals expected around 2027.

Background of the Active Compound

Mazdutide is the first Chinese-developed weight loss drug to receive global attention. The peptide structure (LY3305677) was originally developed by pharma giant Eli Lilly. The Chinese biotech firm Innovent Biologics licensed the rights and rapidly advanced its clinical development. This shows that key innovations in metabolic medicine are increasingly originating in the Asian biotech sector.

Funding Transparency: The pivotal phase-3 study (GLORY-1) was funded by the manufacturer, Innovent Biologics.

Mechanism of Action: A Dual Switch in the Body

Mazdutide mimics the natural intestinal hormone oxyntomodulin, which signals fullness after a meal. As a dual agonist, the drug binds to two distinct receptors in the body simultaneously:

GLP-1 Receptor: Suppresses appetite in the brain, slows gastric emptying, and induces early satiety.
Glucagon Receptor: Stimulates energy expenditure (thermogenesis), promotes direct fat breakdown, and inhibits lipid storage in the liver. This extra fat-burning component differentiates Mazdutide from pure GLP-1 agonists like Wegovy or Ozempic.

Normally, glucagon alone would increase blood glucose levels. However, the simultaneous activation of the GLP-1 pathway compensates for this effect. The result is a highly effective combination of reduced appetite and increased energy expenditure, without destabilizing blood sugar.

Key Clinical Trial Results

GLORY-1: The Pivotal Phase-3 Study (June 2025)

This randomized, double-blind study evaluated 610 obese or overweight Chinese adults over 48 weeks:

At a dose of 4 mg, participants lost an average of 11% of their body weight.
At the higher 6 mg dose, the average weight loss was 14%.
Over one-third of the participants in the 6 mg group achieved a weight loss of 15% or more.

By comparison, Wegovy (semaglutide 2.4 mg) achieves a similar weight loss (approx. 15%) but requires 68 weeks in trials. Mazdutide delivers comparable results in about 30% less time.

High-Dose Phase-2 Results (March 2026)

Another trial evaluated a 9 mg dose in adults with severe obesity. This study demonstrated a 12.8% weight reduction in just 24 weeks.

Meta-Analysis Data (June 2026)

An analysis of multiple trials confirmed other health benefits beyond weight loss:

Waist circumference decreased by an average of 8 cm.
Systolic blood pressure decreased significantly (by approx. 7.6 mmHg).
LDL cholesterol levels were markedly improved.

🔬 Important Notice on Generalizability of the Studies

All major trials so far have been conducted exclusively with Chinese participants. There are two key limitations for Western translation:

Different Obesity Criteria: In China, obesity is defined starting at a body mass index (BMI) of 28 kg/m², whereas European and US standards usually define it starting at a BMI of 30 kg/m².
Ethnic Differences: Because metabolic rates and drug pathways can vary by ethnicity, Western regulatory agencies (EMA/FDA) often require "bridging studies" to prove the drug behaves identically in Western populations.

Additional Benefits: Gout Prevention and Liver Protection

Beyond weight loss, Mazdutide has shown two highly promising properties in trials:

Lowering Uric Acid (Gout Prevention): Excess uric acid can lead to painful joint inflammation and gout. Mazdutide significantly lowers serum uric acid levels—a unique benefit not shared by conventional GLP-1 drugs.
Fatty Liver Treatment (MASH): Since the glucagon component directly activates hepatic lipid metabolism, it reduces fat buildup in the liver. It is currently being investigated as a therapy for metabolic dysfunction-associated steatohepatitis (MASH).

Tolerability and Side Effects

The safety profile aligns with other weight loss drugs. Common side effects affect the gastrointestinal tract and occur mostly during the early titration phase as the body adapts to the compound:

Nausea: Affects about 50% of users at the high 9 mg dose.
Diarrhea & Vomiting: Occurs in approximately 36% to 38% of users.

Side effects were mostly mild to moderate. To minimize these symptoms, the dosage is slowly titrated upwards over 8 to 12 weeks.

Availability and Regulatory Status

Mazdutide has received approval in China from the NMPA for treating obesity and type 2 diabetes.

In Europe and the USA, the drug is currently not approved. Phase-3 clinical trials are ongoing, and regulatory decisions (EMA/FDA) are expected no earlier than 2027.

Warning regarding Online Purchasing: Buying Mazdutide online as a "research chemical" is highly risky and illegal in the EU. These substances bypass quality controls, can be contaminated, and pose severe health hazards.

Conclusion

Mazdutide is a highly promising development in the weight loss drug landscape. The dual-activation mechanism allows rapid fat loss while offering unique liver and uric acid benefits. However, patients in Western markets must await the completion of local trials and official regulatory approval around 2027 for a safe, medically supervised treatment.

Back to Overview